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Purpose:  A new  MRI  parameter  representative  of  active  tumor  burden  is  proposed:  diffusion  volume
(DV),  deﬁned  as  the sum  of  all  the  voxels  within  a tumor  with  apparent  diffusion  coefﬁcient  (ADC)  values
within  a speciﬁc  range.  The  aims  of the  study  were:  (a)  to calculate  DV  on  ADC  maps  in  patients  with
cervical/endometrial  cancer;  (b)  to  correlate  DV  with  histological  grade  (G)  and  risk classiﬁcation;  (c)  to
evaluate  intra/inter-observer  agreement  of DV  calculation.
Materials  and methods:  Fifty-three  patients  with  endometrial  (n  = 28)  and  cervical  (n = 25) cancers  under-
went  pelvic  MRI  with  DWI  sequences.  Both  endometrial  and  cervical  tumors  were  classiﬁed  on  the  basis
of G (G1/G2/G3)  and  FIGO  staging  (low/medium/high-risk).
A semi-automated  segmentation  procedure  was  used  to calculate  the DV.  A freehand  closed  ROI  out-
lined  the  whole  visible  tumor  on the  most  representative  slice  of  ADC  maps  deﬁned  as  the  slice  with the
maximum  diameter  of  the solid  neoplastic  component.  Successively,  two  thresholds  were  generated  on
the basis  of  the mean  and  standard  deviation  (SD)  of  the  ADC  values:  lower  threshold  (LT  =  “mean  minus
three  SD”)  and  higher  threshold  (HT = “mean  plus  one  SD”).  The  closed  ROI  was  expanded  in  3D,  including
all  the contiguous  voxels  with  ADC  values  in the  range  LT-HT  × 10–3  mm2/s.
A  Kruskal–Wallis  test  was  used  to assess  the  differences  in  DV  among  G  and risk groups.
Intra-/inter-observer  variability  for  DV  measurement  was  analyzed  according  to  the  method  of  Bland
and Altman  and  the  intraclass-correlation–coefﬁcient  (ICC).
Results:  DV  values  were  signiﬁcantly  different  among  G and  risk  groups  in both  endometrial  (p <  0.05)  and
cervical  cancers  (p ≤ 0.01).  For  endometrial  cancer,  DV  of  G1  (mean  ± sd:  2.81  ±  3.21  cc)  neoplasms  were
signiﬁcantly  lower  than  G2  (9.44  ± 9.58  cc) and  G3  (11.96  ±  8.0 cc) ones;  moreover,  DV  of  low  risk  cancers
(5.23  ± 8.0  cc)  were  signiﬁcantly  lower  than  medium  (7.28  ± 4.3  cc) and  high  risk  (14.7 ± 9.9  cc)  ones.
For  cervical  cancer,  DV  of G1 (0.31  ±  0.13  cc)  neoplasms  was signiﬁcantly  lower  than  G3  (40.68  ±  45.65
cc)  ones;  moreover,  DV  of  low  risk  neoplasms  (6.98  ± 8.08  cc)  was  signiﬁcantly  lower  than  medium
(21.7  ± 17.13  cc)  and  high  risk  (62.9  ± 51.12  cc)  ones  and  DV  of medium  risk  neoplasms  was  signiﬁcantly
lower  than  high  risk  ones.
The  intra-/inter-observer  variability  for  DV  measurement  showed  an  excellent  correlation  for  both
cancers  (ICC  ≥ 0.86).
Conclusions:  DV  is  an  accurate  i
cancers  with  low  intra-/inter-o
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720-048X/© 2015 Elsevier Ireland Ltd. All rights reserved.ndex  for the  assessment  of G and  risk  classiﬁcation  of cervical/endometrial
bserver  variability.
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. Introduction
The treatment and prognosis of carcinoma of the uterine cervix
nd endometrium are determined by the histological subtype,
rade (G) and FIGO staging. MRI  plays a critical role in the preop-
rative staging of these tumors providing diagnostic information
egarding tumor size, depth of invasion, inﬁltration of contiguous
rgans and lymph node involvement; evaluation of these parame-
ers contributes chieﬂy for treatment planning [1–3].
Diffusion weighted MR  imaging (DWI) is a functional technique
hat looks at the Brownian motion of water in tissues. In biologi-
al tissues, the Brownian motion is restricted by interactions with
ell membranes and macromolecules on a microscopic level as
ell as it is modiﬁed by any architectural tissue changes [4,5].
ncreased tissue cellularity observed in tumors restricts Brownian
otion, which can be quantiﬁed by calculation of the apparent dif-
usion coefﬁcient (ADC). In particular, ADC has been shown to be
nversely correlated with tumor cellularity and it has been clini-
ally applied to distinguish benign from malignant tumors, to assess
umor grade, to delineate tumor extent, as well as to evaluate tumor
reatment response [5–17].
Previous studies regarding the applications of DWI  in gyneco-
ogic diseases demonstrated that cervical cancers have signiﬁcantly
ower ADC values compared to normal cervical tissue [6–9]. Simi-
ar ﬁndings have been found in endometrial cancers, which show
ower ADC values than normal endometrium or benign lesions
10–17]. On the other hand, there is no consensus about the corre-
ation of ADC values with the G of the cervical or the endometrial
umors: some authors did not ﬁnd any signiﬁcant correlation
11,12,14,18], while others found signiﬁcant results only in differ-
ntiating G1 from G3 lesions in endometrial cancers [13]. Moreover,
o signiﬁcant difference was observed among ADC values of cer-
ical cancer when tumors were subgrouped on the basis of FIGO
taging [19]. Therefore, the potential role of ADC values in the eval-
ation of G and FIGO staging of the cervical and endometrial cancer
s still unclear.
Signiﬁcant differences are reported in the technique used to
cquire and to analyze DWI: heterogeneity of acquisition param-
ters (different b-values and acquisition planes), different ROI
lacement methods (single ROI, multiple ROIs, manual ROIs) and
ifferent ADC values analysis (minimum ADC = ADCmin, mean
DC = ADCmean, ADCmin/ADCmean = ADCratio) [6,7,10–15]. Thus,
ack of a current standardized DWI  protocol may  have contributed
o the large variety of results in the relationships between ADC
alues and G and FIGO staging [11–15,18,19].
Methods of ADC maps analysis different from conventional
OI based measurements and able to represent the whole solid
iable component of the neoplasm might overcome the above mis-
atching results. A new strategy to analyze the ADC maps may
e suggested by PET/CT: a positive correlation between tumor
DG uptake and the degree of cellularity has been demonstrated
20–22]; as a consequence of this positive correlation, the metabolic
umor volume (MTV), deﬁned as the volume of tumor tissues with
DG uptake higher than a determinate threshold, has been shown
o estimate the active tumor burden [23]. In the same way, a param-
ter similar to MTV  may  be computed on ADC maps. Because of the
nverse correlation between ADC and tumor cellularity, the volume
f tissue showing ADC values below a determinate threshold may
e representative of the active tumor burden of a neoplasm. Thus,
 diffusion volume (DV) may  be deﬁned as the sum of all the voxels
ithin a tumor with ADC values below a determinate threshold and
ay  represent the active tumor burden. So far, no studies dealing
ith DV in cancer have been published.
Therefore, the purposes of the present study were (1) to develop
 method to calculate the DV on ADC maps in patients with cervical
nd endometrial cancers; (2) to evaluate the intra- and inter-of Radiology 85 (2016) 113–124
observer agreement of the DV calculation; (3) to correlate the DV
as well as the commonly used ADC values with the histological
tumor grade and the risk classiﬁcation and to compare directly the
performance of these parameters.
2. Materials and methods
2.1. Population selection
This retrospective study enrolled all patients with endometrial
or cervical cancer who  underwent pelvic MRI  with DWI  sequences
at our institution between November 2010 and September 2012.
The inclusion criterion was  histologically proven cervical or
endometrial cancer. The exclusion criterion was previous preop-
erative chemo- and/or radio-therapy before MRI  examination.
The study was  approved by local research ethics committee.
Before MRI  scan, all patients gave their informed consent to per-
form examination as well as the permission for the use of their
anonymised data for research purposes. This procedure represents
a standard protocol in our institution.
The clinical presentation, the histological type, the G and the
staging for each patient were obtained from the clinical records of
the hospital. The staging was determined according to the guide-
lines of the International Federation of Gynecology and Obstetrics
(FIGO).
According to G and FIGO staging, endometrial cancers were
stratiﬁed in three classes of risk determining the management
strategy and prognosis (Table 1): low risk (stage IA with G1 or G2),
medium risk (stage IA with G3 or stage IB with any G or stage
II) and high risk (stage III or IV) [24,25]. Similarly, according to
FIGO staging, cervical cancers were stratiﬁed in three classes of
risk determining the management strategy and prognosis (Table 1):
low risk (early stage disease: stage IA or IB1 or IIA1), medium risk
(early stage bulky disease: stage IB2 or IIA2) and high risk (locally
advanced disease: stage IIB or III or IV) [25,26]. The deﬁnition “bulky
disease” identiﬁes early stage (IB and IIA) neoplasms with greatest
diameter > 4 cm.  An increased risk of nodal involvement is associ-
ated to these lesions [25,26].
2.2. MRI  technique
Images were acquired using a 3T MR  scanner (Magnetom
Trio Siemens, Erlangen, Germany) equipped with a multichannel
phased array coil. For all sequences, the ﬁeld of view (FOV) and
the number of slices were optimized for each individual patient
to cover the anatomy of interest. Axial and coronal planes were
acquired perpendicular and parallel to the long axis of the uterine
body for endometrial cancer and of cervix for cervical cancer.
All patients underwent the following MRI  unenhanced and
contrast-enhanced protocol:
- T1-weighted turbo spin-echo (TSE) in the axial-oblique plane (TR
828 ms;  TE 10 ms; slice thickness 4 mm;  matrix size 256 × 256;
averages 3; ﬂip angle 140◦; acquisition time 2.26 min);
- T2-weighted TSE in the sagittal plane (TR 4500 ms; TE 102 ms;
slice thickness 4 mm;  matrix size 256 × 256; averages 3; acquisi-
tion time 2.26 min);
- T2-weighted TSE in the axial-oblique plane with and without
fat suppression (TR 5000 ms;  TE 94 ms;  slice thickness 4 mm;
matrix size 256 × 256; ﬂip angle 140◦, averages 2; acquisition
time 2 min);
- T2-weighted TSE in the coronal-oblique plane (TR 6000 ms;  TE
106 ms;  slice thickness 4 mm;  matrix size 256 × 256; averages 2;
ﬂip angle 120◦; acquisition time 2.14 min);
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Table  1
Treatment and prognosis of endometrial and cervical cancer stratiﬁed for class of risk.
Endometrial adenocarcinoma Low risk Medium risk High risk
Treatment Total hysterectomy with bilateral
salpingo-oophorectomy
Radical hysterectomy with bilateral
salpingo-oophorectomy and pelvic
lymphadenectomy
Para-aortic lymphadenectomy may be
considered
RT is indicated
CT may  be considered
Maximal surgical debulking in patients with a good
performance status associated to CT/RT (stage III)
Anterior and posterior pelvic exenteration associated
to CT/RT (stage IVa)
Palliative surgery associated to CT/RT (stage IVb)
Prognosis Five years survival rate:
>95%
Five years survival rate:
80–90%
Five years survival rate:
Stage III: 55–65%
Stage IV: 25–35%
Cervical carcinoma Low risk Medium risk High risk
Treatment Stage IA
•  Conization or trachelectomy (if
fertility is to be preserved)
•  Total or radical hysterectomy (if
fertility is not to be preserved)
•  PLND if LVSI
Stage IB1 and IIA1
•  Radical hysterectomy and PLND
•  RT may  be considered
Radical hysterectomy and PLND
associated to RT and CT
Combination of RT/CT
Prognosis Five years survival rate: Five years survival rate: Five years survival rate:
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Stage IB1 and IIA1: 70–85%
65–75%
 T1-weighted volume interpolated breath hold examination
(VIBE) (TR 3.30 ms;  TE 1.17ms; slice thickness 2 mm;  matrix
size 256 × 256; averages 1; ﬂip angle 13◦; acquisition time 20 s
for each phase) before and after bolus injection of gadopen-
tetate dimeglumine (Magnevist; Berlex Laboratories; dose:
0.2 mmol/kg; injection by a power injector; rate of injection:
3 ml/sec followed by 20 ml  of normal saline ﬂush) at 30, 60, 120 s
in the sagittal plane and at 180 s in the axial-oblique plane;
Before contrast enhanced T1-VIBE sequences, DWI  was  obtained
sing a single-shot-echo-planar imaging sequence under free
reathing with chemical shift selective fat-suppression technique
SPAIR) and parallel imaging technique (GRAPPA-2). The following
arameters were used in the axial-oblique planes (TR 5700 ms,  TE
9 ms,  slice thickness 4 mm;  matrix size 128 × 128; averages 5; b-
alue 0, 500 and 1000 s/mm2, acquisition time 3.07 min) and in the
agittal planes (TR 5000ms, TE 70 ms,  slice thickness 4 mm;  matrix
ize 128 × 128; averages 5; b-value 0, 500 and 1000 s/mm2, acqui-
ition time 3.10 min). Following the acquisition of b = 0 images,
otion-probing gradients in three orthogonal orientations were
equentially applied for each b value. ADC map  was computed from
he b = 0 images and the diffusion-weighted images reconstructed
or b = 500 and 1000 s/mm2. The standard software on the imaging
onsole (Syngo VE 36 A, Siemens, Erlangen, Germany) was used for
DC map  calculation.
.3. ADC maps analysis
Five different radiologists (each one with at least 4 years of
xperience in female pelvis MR  imaging) were asked to analyse
he images: three of them applied a different ROI method to calcu-
ate the conventional ADC values (S.S., L.P., M.S.) and two of them
E.L., S.D.) deﬁned the DV. The choice to select ﬁve radiologists was
ictated by the necessity to prevent that the application of each
ethod of analysis might be inﬂuenced by the others. In order to
erform inter- and intra-observer analysis of DV, two  radiologists
ere involved and one of them was asked to repeat the procedure
ne month later (S.D.).Stage II B: 55–65%
Stage III: 25–40%
Stage IV: <15%
All MRI  sequences performed were available to the readers at the
time of ADC maps analysis. Each reader was  asked to identify the
tumor, to deﬁne its contours and to recognize the cystic/necrotic
portions of the lesion. Each reader used the unenhanced, contrast-
enhanced and DWI  images to deﬁne the solid part of the tumor
and its contours. The cystic/necrotic portions were deﬁned as areas
with ﬂuid-like hyperintense signal on T2 images and DWI  images
obtained at b0 value and without enhancement on T1 VIBE lesions.
Each sequence could be inspected individually as well as compara-
tively with the others; moreover, MRI  fused-images were obtained
if necessary. The ROIs placement was made using visual corre-
lation of the ADC maps with information on the corresponding
unenhanced, contrast-enhanced and DWI  images. The readers were
blinded to each other’s results, clinical patient data and pathology
reports.
2.3.1. ADC values
Three different radiologists analyzed the ADC maps applying
each one a method. The method A (S.S.) consisted in placing a sin-
gular ROI, as large as possible, within the tumor on ADC maps, in
the slice containing the largest solid tumor area. The method B (L.P.)
consisted in drawing ﬁve circular ROIs, where possible, approxi-
mately of 5 mm2, within the tumor on ADC maps, in each slice in
which the tumor was  detectable. The method C (M.S.) consisted in
outlining one ROI which included the whole neoplastic area on ADC
maps, in each slice in which the tumor was  detectable.
For each patient the ADC values were calculated both in the
axial-oblique and the sagittal planes.
The ROIs were always placed in the solid components of the
tumors, avoiding cystic/necrotic areas.
The ADC values were obtained in terms of ADC × 10–3 mm2/s
(millimeters squared/second).
ADCmin, ADCmean and ADCratio were calculated for each
method.When using the method A, ADCmin and ADCmean were
extracted in the singular ROI. For the method B, ADCmin was the
minimum value of ADC obtained among all the circular placed ROIs,
while ADCmean was calculated as the average of all the ADCmean
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Fig. 1. a, b, c and d. Calculation of diffusion volume (DV) in a patient with endometrial cancer. The most representative slice of the neoplasm was selected on ADC maps (a).
The  solid lesion was  outlined manually with a line; mean and standard deviation (SD) of the ADC values were calculated on the resulting freehand ROI; two thresholds were
successively generated: lower threshold (LT) deﬁned as “mean value minus three SD” and higher threshold (HT) deﬁned as “mean value plus one SD” (b). The closed surface
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xtracted by each ROI. In the method C, ADCmin was considered
s the minimum value of the total slices within the tumor, while
DCmean was calculated as the average of mean ADC values in each
lice.
.3.2. Diffusion volume (DV)
A semi-automated segmentation procedure written in Matlab
The Matworks) was used for image analysis. The goal of the seg-
entation procedure was  to select the solid cellular parts of the
eoplasm and to exclude the cystic/necrotic/inﬂammatory ones.
The radiologist selected the most representative slice, deﬁned as
he slice with the maximum diameter of the solid component of the
umor, and successively outlined manually the whole visible solid
eoplastic component with a line. Mean and standard deviation
SD) of the ADC values were calculated on the resulting freehand
OI. Two thresholds were successively generated: lower threshold
LT) deﬁned as “mean value minus three SD” and higher thresh-
ld (HT) deﬁned as “mean value plus one SD”. The closed surface
epresented by the freehand ROI was expanded in 3D, including,
teratively, all the contiguous voxels with ADC values in the range
T-HT. At the end of process, the operator checked the ﬁnal 3D ROI
o verify that no voxel outside the contours of the solid neoplas-
ic component was included, eventually deleted the misclassiﬁed
oxels and edited the ﬁnal 3D-ROI (Fig. 1).
As stated above, the cystic/necrotic portions were eliminated on
he basis of the visual comparison of ADC maps with T2-weighted
nd contrast-enhanced images, however we estimated that a more
estrictive quantitatively approach on the ADC maps prevented the
rroneous inclusion of components different from solid portions
f the tumor. The asymmetric range switched toward the lower in 3D including all the contiguous voxels with ADC values in the range LT–HT, as
 represents the left side of the tumor respect to the representative slice, while the
ADC values was suggested by the inverse correlation between ADC
and tumor cellularity (the lower ADC correspond to the higher
cellular density voxels) as well as the lower values of ADC for malig-
nant cervical and endometrial tumor respect to normal tissues or
benign lesions. As a result, the HT represented a further strategy
to exclude inﬂammatory changes accompanying the tumor as well
as cystic/necrotic components not identiﬁed by visual comparison
with unenhanced and contrast-enhanced MR images and to pre-
vent the erroneous inclusion of contiguous normal tissues. The LT
was intended to exclude the noisy voxels.
The whole procedure was  performed for both the sagittal and
the axial images by two radiologists for inter-observer variability
(E.L. and S.D.). One of the two observers repeated the procedure
one month later to evaluate intra-observer variability of the results
(S.D.).
Only the primary tumors were included in the analysis, and thus
pelvic lymph nodes were not considered for DV analysis.
2.4. Morphological volume calculated on T2 images
Another radiologist (F.R.) with at least 4 years of experience in
female pelvis MR  imaging outlined the whole visible tumor with
a closed line in each slice in which the tumor was detectable. The
closed line included only the solid portions of the tumors, avoiding
ﬂuid/necrotic portions. The T2 volume was  automatically com-
puted on the basis of each slice area, the slice thickness and the
inter-slice gap.
The procedure was  executed for both the sagittal and axial
images.
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The T2 volume was considered equal to zero in those patients in
hom the lesion was not deﬁned on T2 images and its identiﬁcation
ould be obtained thanks to the other sets of images.
.5. Statistical analysis
Kruskal–Wallis test with post-hoc analysis was used to assess
he statistical differences in measured parameters among grad-
ng groups as well as among risk groups a nonparametric. A p
alue < 0.05 was considered signiﬁcant.
Intra- and inter- observer variability for tumor volume mea-
urements was analyzed according to the method of Bland and
ltman and by calculating intraclass correlation coefﬁcient (ICC)
0.00–0.2 poor, 0.21–04 fair, 0.41–0.6 moderate, 0.61–0.80 good
nd 0.81–1.00 excellent correlation) with corresponding 95% con-
dence interval (CI). In the same way, the difference between axial
nd sagittal measurements was evaluated.
Receiver operator characteristic (ROC) curve analysis was per-
ormed to evaluate the impact of the different parameters on both and risk classiﬁcation. ROC curves were ﬁtted for each param-
ter and task, and the area under the curve (AUC) was used as
erformance index. The 95% conﬁdence interval for the area was
sed to test the hypothesis that the theoretical area was  0.5. If themetrial cancers on the y axis (a and c: axial DV; b and d: sagittal DV) according to
conﬁdence interval did not include the 0.5 value, then there was
evidence that the test had an ability to distinguish between the two
groups. A p value < 0.05 was  considered signiﬁcant. The method of
Delong was  used in order to comparing the areas under correlated
receiver operating characteristic curves.
MedCalc Statistical Software version 13.1.2 was used for sta-
tistical analysis (MedCalc Software bvba, Ostend, Belgium; http://
www.medcalc.org; 2014).
3. Results
3.1. Patients
The study group consisted of 53 patients, 28 with histologi-
cally proven endometrial cancer (age range, 31–85 years; mean age
58 ± 117 years) and 25 with histologically proven cervical cancer
(age range, 22–73 years; mean age 47 ± 121 years).
Thirty-two patients were post menopausal (21 with endome-
trial cancer, 11 with cervical cancer).Two  clinical scenarios were observed before MRI: (1) patients
with highly suspicious lesions at transvaginal ultrasonography
examination (n 28); (2) patients with positive hysteroscopy for
endometrial or cervical cancer (n 25).
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Table 2
Clinical presentation, histological type, grade, FIGO staging and classes of risk of endometrial and cervical carcinoma.
Endometrial adenocarcinoma n◦ Cervical carcinoma n◦
Clinical presentation Metrorrhagia 9 Metrorrhagia 9
Menometrorrhagia 2 Menometrorrhagia 2
Vaginal bleeding 12 Vaginal bleeding 7
Asymptomatic 5 Asymptomatic 7
Histological type Endometrioid 26 Squamous 25
Sarcomatoid 1
Squamous 1
Grade Grade 1 8 Grade 1 2
Grade 2 13 Grade 2 3
Grade 3* 7 Grade 3 20
FIGO  staging IA 14 IA2 2
IB  11 IB1 7
IIIA  1 IB2 1
IIIC1  2 IIA1 2
IIA2 2
IIB 5
IIIB 4
IVA 1
IVB 1
Classes of risk Low risk 13 Low risk 11
Medium risk 8 Medium risk 3
High  risk 7 High risk 11
* The sarcomatoid and squamous adenocarcinomas were taken to represent the equivalent of grade 3 endometrioid adenocarcinomas because they are considered to be
aggressive histological subtypes and are associated with a worse prognosis than endometrioid adenocarcinoma.
Table 3
Mean, standard deviation (sd) and range of DV and T2 volume for endometrial and cervical cancer. DV and T2 volume are expressed in cubic centimeter.
Endometrial cancer Cervical cancer
Axial Sagittal Axial Sagittal
Diffusion volume (DV)
Mean ± sd 9.74 ± 8.99 10.26 ± 9.21 33.33 ± 36.37 32.82 ± 34.23
Range  0.45–33.66 0.39–35.81 0.20–205.33 0.19–181.67
12.6 ± 11.5 36.86 ± 35.6 35.69 ± 34.82
0–36.8 0–215 0–198
b
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Fig. 3. Inter-planes reproducibility for diffusion volume (DV) measurements
(expressed in cc) performed in axial and sagittal planes for the endometrial can-
cer. Bland–Altman plots of the average of axial and sagittal DV (x axis) against the
difference between axial DV and sagittal DV (y axis). The continuous line representsT2  volume
Mean ± sd 12.4 ± 11.5 
Range  0–36.45 
No therapy (surgery, chemo-radiotherapy) was performed
efore MRI  study.
The clinical presentation, the histological type, the G, the FIGO
taging and the risk classiﬁcation classes are summarized in Table 2.
.2. Images
The primary tumor was deﬁned at least in one set of images in all
8 patients with endometrial cancer and 25 patients with cervical
ancers.
.2.1. Endometrial cancer
Mean values and range values of DV, ADCmin, ADCmean and
DCratio for each ROI protocol and T2 volume are displayed in
ables 3 and 4.
Both axial and sagittal DV values were signiﬁcantly (p = 0.012;
 = 0,021 respectively) different among G grade groups; in particu-
ar, post-hoc analysis revealed a signiﬁcant difference of G1 vs G2
nd G3 (Fig. 2a and Fig. 2b). Similarly, both axial and sagittal DV
alues were signiﬁcantly (p = 0.014; p = 0.02 respectively) different
mong risk groups; in particular, post-hoc analysis revealed a sig-
iﬁcant difference of the low risk versus the medium and the high
isk (Fig. 2c and Fig. 2d). Moreover, the DV measures obtained on
xial and sagittal planes showed an excellent correlation (Fig. 3).
None of the other variables (ADCmin, ADCmean, ADCratio) using
ny of the method A, B and C showed signiﬁcant difference at
ruskal–Wallis analysis.
Both axial and sagittal T2 volumes were not signiﬁcant at
ruskal–Wallis analysis among G-grade groups and risk groups.the mean absolute difference in DV between the two planes; the dashed lines rep-
resent the 95% conﬁdence intervals of the mean differences. The ICC was excellent
(ICC: 0.94; 95% CI: 0.93–0.99).3.2.2. Cervical cancer
Mean values, standard deviation and range of DV, ADCmin,
ADCmean and ADCratio for each ROI protocol and T2 volume are
displayed in Table 3 and 4.
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Fig. 4. a, b, c and d. Mean and standard deviation of DV values (expressed in cc) of cervica
(a  and b) and risk group classiﬁcation (c and d) reported on the x axis.
Fig. 5. Inter-planes reproducibility for diffusion volume (DV) measurements per-
formed in axial and sagittal planes for cervical cancer. Bland–Altman plots of the
average of axial and sagittal DV (x axis) against the difference between axial DV and
sagittal DV (y axis). The continuous line represents the mean absolute difference in
DV  between the two planes; the dashed lines represent the 95% conﬁdence intervals
of  the mean differences. The ICC was excellent (ICC: 0.97; 95% CI: 0.95–0.99).l cancers on the y axis (a and c: axial DV; b and d: sagittal DV) according to grading
Both axial and sagittal DV values were signiﬁcantly (p = 0.01)
different among G grade groups; in particular, post-hoc analysis
revealed a signiﬁcant difference between G1 and G3 (Fig. 4a and
b). Similarly, both axial and sagittal DV values were signiﬁcantly
(p < 0.001) different among all the risk groups (Fig. 4c and d). More-
over, the DV measures obtained on both axial and sagittal planes
showed an excellent correlation (Fig. 5).
Relatively to the method A, the axial ADCmean
(G1: 1.17 × 10–3 mm2/s; G2: 0.84 × 10–3 mm2/s; G3:
0.75 × 10–3 mm2/s) and the axial ADCmin (G1 0.96 × 10–3 mm2/s;
G2: 0.75 × 10–3 mm2/s; G3: 0.56 × 10–3 mm2/s) were signiﬁcantly
(p < 0.05) different among G grade groups; in particular, post-hoc
analysis revealed a signiﬁcant difference of G1 vs G3. None of the
variables of method A was able to discriminate among the risk
groups.
Relatively to the method B, the axial ADCmean (early stage
1.04 × 10–3 mm2/s; early stage bulky disease: 0.90 × 10–3 mm2/s;
locally advanced disease: 0.79 × 10–3 mm2/s) was signiﬁcantly dif-
ferent (p = 0.01) among the risk groups; in particular, post-hoc
analysis revealed a signiﬁcant difference of the early stage vs the
early stage bulky disease and the locally advanced disease. None
of the variables of method B was able to discriminate among the G
grade groups.
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Table 4
Mean, standard deviation (sd) and range of ADCmean, ADCmin, ADCratio of each method for endometrial and cervical cancer. ADCmin and ADCmean are expressed in
10−3 mm2/s.
Endometrial cancer Cervical cancer
Axial Sagittal Axial Sagittal
Method A
ADCmean
Mean ± sd 0.86 ± 0.17 0.87 ± 0.16 0.88 ± 0.16 0.89 ± 0.20
Range  0.58–1.30 0.55–1.20 0.57–1.37 0.56–1.53
ADCmin
Mean  ± sd 0.68 ± 0.16 0.67 ± 0.13 0.73 ± 0.15 0. 47 ± 0.17
Range  0.37–1.10 0.42–0.91 0.37–1.08 0.44–1.25
ADCratio
Mean  ± sd 0.79 ± 0.06 0.77 ± 0.07 0.83 ± 0.06 0.83 ± 0.04
Range  0.56–0.89 0.6–0,99 0.66–0.98 0.77–0,90
Method B
ADCmean
Mean ± sd 0.93 ± 0.16 0.95 ± 0.17 0.94 ± 0.15 0.97 ± 0.20
Range  0.70–1.3 0.74–1.46 0.69–1.33 0.66–1.33
ADCmin
Mean  ± sd 0.63 ± 0.15 0.61 ± 0.16 0.70 ± 0.16 0.70 ± 0.17
Range  0.37–1.09 0.42–1.21 0.39–1.06 0.44–1.00
ADCratio
Mean ± sd 0.68 ± 0.10 0.65 ± 0.10 0.73 ± 0.07 0.72 ± 0.08
Range  0.53–0.84 0.57–0.79 0.56–0.80 0.66–0.76
Method C
ADCmean
Mean ± sd 0.95 ± 0.18 0.96 ± 0.18 0.98 ± 0.11 1.00 ± 0.12
Range  0.68–1.52 0.68–1.49 0.73–1.14 0.72–1.10
ADCmin
Mean  ± sd 0.66 ± 0.20 0.66 ± 0.19 0.66 ± 0.13 0.67 ± 0.13
Range  0.37–1.26 0.40–1.27 0.39–0.86 0.44–0.88
 ± 0.1
–0.86
A
a
a
t
d
d
e
t
3
w
a
3
t
f
c
c
c
o
n
t
T
t
(
AADCratio
Mean  ± sd 0.68 ± 0.11 0.68
Range  0.42–0.83 0.42
Relatively to the C method, none of the variables (ADCmin,
DCmean, ADCratio) was  signiﬁcant different at Kruskal–Wallis
nalysis.
Kruskal–Wallis analysis did not show any signiﬁcant difference
mong G grade for both axial and sagittal T2 volumes. On the con-
rary, both axial and sagittal T2 volumes were signiﬁcantly (p = 0.01)
ifferent among the risk groups; in particular, post-hoc analysis
ifferentiated signiﬁcantly the locally advanced disease from the
arly stage and the early stage bulky disease on axial images and
he locally advanced disease from the early stage on sagittal images.
.2.3. Intra- and inter-observer variability of diffusion volume.
The intra-observer variability and the inter-observer variability
ere excellent (ICC > 0.81) relatively to both endometrial (Fig. 6)
nd cervical cancer (Fig. 7).
.2.4. ROC analysis
In order to evaluate and compare the clinical impact, if any, of
he different parameters evaluated, ROC analysis was  performed
or both G and risk classiﬁcation. Actually, patients with G1 and G2
ancers were grouped, as well as, patients with low and medium
lass of risk.
In endometrial cancer group, the ROC-AUC for DV was statisti-
ally signiﬁcant for both G and risk classiﬁcation (Tables 5 and 6),
n the contrary the ROC-AUCs for all the other parameters were
ot signiﬁcant.
In cervical cancer group, only the ROC-AUC for the DV was  statis-
ically signiﬁcant for both G and risk classiﬁcation (Tables 7 and 8).
he ROC-AUCs for all the other parameters were not signiﬁcant for
he risk classiﬁcation. On the contrary the ROC-AUCs for ADCratio
method A and C) and T2 volume were statistically signiﬁcant for G.
lthough no signiﬁcant difference was observed when compared0 0.67 ± 0.08 0.67 ± 0.07
 0.52–0.84 0.53–0.79
the ROC-AUCs for DV, T2 volume and ADCratio, ROC-AUC for DV
showed a higher value than the others.
4. Discussion
Quantitative imaging characterization using advanced tech-
niques is currently an ongoing topic in oncology. The results of this
study suggest that DV shows low intra-/inter-observer variability
and correlates with both grading and risk classiﬁcation of cervical
and endometrial cancers. The DV values were signiﬁcantly different
among G and risk groups in both endometrial and cervical cancers.
Moreover, the DV performs better than more commonly used ADC
values, as shown by the ROC analysis.
The potential role of ADC values in the preoperative evalua-
tion of G and risk classiﬁcation of cervical and endometrial cancer
is controversial [7,10,12–14]. The heterogeneous reported results
may  be in part explained by several different issues: the ADCmin
value reﬂects the functional activity of only a small sample of the
total ongoing neoplastic process; the ADCmean calculation may be
inﬂuenced by the ROI positioning and size; the ADCratio depends
on the accuracy of both ADCmin and ADCmean values. Therefore,
these controversial results suggest the necessity to ﬁnd an alter-
native method to analyze the ADC maps. In the present study, the
DV overcomes the limit of each ADC value and each method of ADC
measurement in the assessment of grading and risk classiﬁcation of
both cervical and endometrial cancers. The DV selects the portions
of the tumor with high cellular densities, which represent the active
tumor burden and indicate the aggressiveness of the neoplasm.
This observation is corroborated by the following previous ﬁndings
about PET/CT and PET/MRI: (a) the MTV  represents more accurately
than the maximum standardized uptake value (SUVmax) the active
tumor burden [23,27–29]; (b) tumor subvolumes with increased
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Fig. 6. a, b, c, d Intra- (a and b) and inter- (c and d) observers reproducibility for diffusion volume (DV) measurements (expressed in cc) in axial (a and c) and sagittal planes
(b  and d) for endometrial cancer. For the intra-observer reproducibility, the same operator calculated twice the DV in both axial and sagittal planes: axial 1 DV,  axial 2 DV,
sagittal 1 DV and sagittal 2 DV of the same operator were obtained. For the inter-observers reproducibility, a second operator calculated the DV in both axial and sagittal
planes: axial 2 DV and sagittal 2 DV of the second operator were obtained. Bland–Altman plots of the average of the axial DV (x axis) against the difference between axial
DV  (y axis) of the two measurements performed by the same operator (a) and by the two  operators (c); the continuous line represents the mean absolute difference in DV
between the two measures; the dashed lines represent the 95% conﬁdence intervals of the mean differences. Bland–Altman plots of the intra-observer reproducibility (b)
and  inter-observer reproducibility (d) for sagittal plane.
Table 5
ROC-AUCs relative to G classiﬁcation of endometrial cancer.
AUC SE 95% C.I. p Value
ADCmean (method A) 0.609 0.124 0.407–0.786 0.3788
ADCmean (method B) 0.636 0.127 0.434–0.808 0.2824
ADCmean (method C) 0.575 0.131 0.375–0.758 0.5688
ADCmin (method A) 0.599 0.121 0.398–0.778 0.4163
ADCmin (method B) 0.653 0.124 0.451–0.822 0.2158
ADCmin (method C) 0.650 0.132 0.447–0.819 0.2554
ADCratio (method A) 0.541 0.108 0.343–0.729 0.7050
ADCratio (method B) 0.531 0.138 0.334–0.720 0.8245
ADCratio (method C) 0.619 0.134 0.417–0.795 0.3730
T2  volume 0.683 0.127 0.468–0.852 0.1521
DV  0.762 0.106 0.564–0.901 0.0137*
A
m
o
uUC: Area under the curve; SE: Standard error; C.I.: Conﬁdence interval.
* A p value < 0.05 was  considered signiﬁcant.etabolic activity on FDG-PET also have more restricted diffusion
n DWI, indicating greater cell density [30–31].
Since both endometrial and cervical cancers show ADC val-
es signiﬁcantly lower than normal endometrial/cervical tissue orbenign lesions [6,7,10–15] as well as the viable solid neoplastic tis-
sue respect to tumor necrosis [32], we set an asymmetric window
around the ADCmean shifted towards the lowest values to make
the DV a parameter representative of the active malignant tumor
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Fig. 7. a, b, c, d Intra- (a and b) and inter- (c and d) observers reproducibility for the diffusion volume (DV) measurements expressed in cc in axial (a and c) and sagittal planes
(b  and d) for the cervical cancer. For the intra-observer reproducibility, the same operator calculated twice the DV in both axial and sagittal planes: axial 1 DV,  axial 2 DV,
sagittal  1 DV and sagittal 2 DV of the same operator were obtained. For the inter-observers reproducibility, a second operator calculated the DV in both axial and sagittal
planes: axial 2 DV and sagittal 2 DV of the second operator were obtained. Bland–Altman plots of the average of the axial DV (x axis) against the difference between axial
DV  (y axis) of the two measurements performed by the same operator (a) and by the two operators (c); the continuous line represents the mean absolute difference in DV
between  the two measures; the dashed lines represent the 95% conﬁdence intervals of the mean differences. Bland–Altman plots of the intra-observer reproducibility (b)
and  inter-observer reproducibility (d) for sagittal plane.
Table 6
ROC-AUCs relative to risk classiﬁcation of endometrial cancer.
AUC SE 95% C.I. p Value
ADCmean (method A) 0.541 0.120 0.343–0.729 0.7342
ADCmean (method B) 0.602 0.123 0.401–0.781 0.4051
ADCmean (method C) 0.558 0.131 0.359–0.74 0.6589
ADCmin (method A) 0.514 0.118 0.319–0.706 0.9085
ADCmin (method B) 0.626 0.121 0.424–0.800 0.2968
ADCmin (method C) 0.622 0.129 0.421–0.797 0.3413
ADCratio (method A) 0.650 0.103 0.447–0.819 0.1445
ADCratio (method B) 0.639 0.118 0.437–0.811 0.2358
ADCratio (method C) 0.585 0.130 0.385–0.767 0.5129
T2  volume 0.714 0.128 0.500–0.875 0.0929
DV  0.816 0.105 0.625–0.936 0.0025*
A
b
t
t
aUC: Area under the curve; SE: Standard error; C.I.: Conﬁdence interval.
* A p value < 0.05 was  considered signiﬁcant.
urden. As stated in material and methods section, the necessity
o ﬁx the HT (“mean value plus one SD”) was intended to exclude
he inactive regions of the tumor such as inﬂammatory changes
ccompanying the tumor as well as the cystic/necrotic componentsnot identiﬁed by visual comparison with unenhanced and contrast-
enhanced MR  images and to prevent the erroneous inclusion of
contiguous normal tissues, while the LT (“mean value minus three
SD”) was preferred to the lowest ADC values because the latter can
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Table  7
ROC-AUCs relative to G classiﬁcation of cervical cancer.
AUC SE 95% C.I. p Value
ADCmean (method A) 0.595 0.188 0.382–0.785 0.6126
ADCmean (method B) 0.680 0.163 0.465–0.851 0.2706
ADCmean (method C) 0.620 0.166 0.406–0.805 0.4692
ADCmin (method A) 0.520 0.200 0.313–0.722 0.9205
ADCmin (method B) 0.575 0.159 0.363–0.768 0.6381
ADCmin (method C) 0.675 0.132 0.460–0.847 0.1833
ADCratio (method A) 0.850 0.111 0.651–0.960 0.0015*
ADCratio (method B) 0.520 0.159 0.313–0.722 0.8996
ADCratio (method C) 0.850 0.111 0.651–0.960 0.0016*
T2 volume 0.825 0.0865 0.605–0.952 0.0002*
DV 0.895 0.0728 0.707–0.981 <0.0001*
AUC: Area under the curve; SE: Standard error; C.I.: Conﬁdence interval.
* A p value < 0.05 was  considered signiﬁcant.
Table 8
ROC-AUCs relative to risk classiﬁcation of cervical cancer.
AUC SE 95% C.I. p Value
ADCmean (method A) 0.610 0.117 0.397–0.797 0.3464
ADCmean (method B) 0.685 0.108 0.470–0.854 0.0868
ADCmean (method C) 0.513 0.119 0.307–0.716 0.9134
ADCmin (method A) 0.503 0.120 0.298–0.707 0.9784
ADCmin (method B) 0.558 0.121 0.348–0.755 0.6292
ADCmin (method C) 0.513 0.121 0.307–0.716 0.9147
ADCratio (method A) 0.692 0.108 0.477–0.859 0.0749
ADCratio (method B) 0.565 0.119 0.354–0.760 0.5864
ADCratio (method C) 0.513 0.120 0.307–0.716 0.9136
T2  volume 0.839 0.102 0.621–0.959 0.0929
DV  0.948 0.0403 0.779–0.997 <0.0001*
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aUC: Area under the curve; SE: Standard error; C.I.: Conﬁdence interval.
* A p value < 0.05 was  considered signiﬁcant.
e subject to noise or artifacts contamination. Relative to this last
nstance, very low (non biologically meaningful) ADC values may  be
bserved also in regions with low signal in b0 images in which the
oxels are affected by random signal loss due to noise or artifacts.
n these voxels, ADC values can be very low considering that the
DC calculation is based on the ratio between the signal measured
n the b0 and the b1 images.
Every method of segmentation requests the choice of a thresh-
ld or a range and this choice may  represent a source of bias. For
his reason the threshold or the range has to be chosen on the basis
f reasonable criteria. Moreover, every method of segmentation
ay  be improved. The example of MTV  is that different methods of
egmentation have been proposed as ﬁxed (absolute SUVmax, per-
entage of SUVmax) or gradient thresholds [33–36]. That means
hat the MTV  is still largely used as biological imaging parame-
er, although the method to calculate it has changed in the course
f time. Some observations have to be reported on the thresholds
sed in our study: (1) testing three different couple of thresholds
“ADCmean minus 3/plus 1 SD”; “ADCmean minus 2,5/plus 1,5 SD”;
ADCmean minus 2/plus 2 SD”) in 8 patients, we  observed that the
ange “ADCmean minus 3/plus 1 SD” recruited few voxels located
utside the solid part of the tumor in only a patient, with an over-
ll better performance than the others ranges; setting the range
ADCmean minus 3/plus 1 SD”, the manually editing of the auto-
ated segmentation did not request robust corrections in any of the
3 patients; (2) the range “ADCmean minus 3/plus 1 SD” is based
n reasonable and restrictive thresholds ﬁxed to include high cel-
ular density voxels; (3) the range “ADCmean minus 3/plus 1 SD”
ffered an excellent correlation (ICC > 0.81) between the measure-
ents obtained on the axial and the sagittal planes, an excellent
greement (ICC > 0.81) at the intra- and inter-observer variability,
 signiﬁcant discrimination of the grading and the risk classiﬁca-
ion of both cervical and endometrial cancers; (4) the DV appears
s a valid biological imaging parameter. Of course, the method ofsegmentation we propose in the present study may  be improved
and reﬁned with increasing data collection and analysis.
The volumes expressed by the DV were different from those
computed on T2 images and correlated signiﬁcantly with the G
and the risk classiﬁcation. This ﬁnding suggests that the DV and
the morphological volume represent different aspects of a neo-
plasm and that the former is not exclusively deﬁned by the guide
of anatomical images. A possible explanation of this result is that
the inﬂammatory changes accompanying the neoplastic inﬁltration
gives an overestimation of tumor size on T2 images. The asym-
metric window around the ADCmean used to calculate the DV
may  allow excluding also the inﬂammatory perilesional reaction.
A similar discrepancy was  observed between FDG-PET volume (at
SUVmax cut-off percentage of 40%) and T2-weighted volume in cer-
vical cancer with PET/MRI [37]. On the other hand, the same Authors
reported no signiﬁcant difference between FDG-PET (at SUVmax
cut-off percentage of 35% and 40%), T2-weighted and DWI  volumes
in cervical cancer with PET/MRI [31]. The main difference with our
study is related to the method of tumor outlining: the Authors
selected the whole gross neoplastic volume, while we looked only
at the solid parts. These results as well as ours suggest that, rather
than demonstrating overlap or discrepancy between morphologi-
cal and functional volume, it is crucial to ﬁnd and emphasize which
morphological and functional information may be representative
of the tumor biological characteristics.
Recently, the quantitative histogram analysis of ADC maps has
been proposed in the identiﬁcation of adverse histological char-
acteristics of stage I cervical carcinoma [18]. We did not consider
using the quantitative histogram analysis in our population because
the method looks at the heterogeneity evaluating the whole neo-
plasm (solid cellular, inﬂammatory, cystic/necrotic parts) rather
than the active neoplastic burden which represents the goal of our
research. Moreover, the question about the choice of threshold val-
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es would be anyway present in getting DV from the percentiles or
he skew or the kurtosis measurements.
The variations in ROI size and positioning have been showed to
ave a signiﬁcant effect on tumor ADC values and inter-observer
ariability in patients with rectal cancer [38]. Moreover, it is not
learly deﬁned which ADC value (ADCmin, ADCmean, ADCratio)
s more representative of tumor aggressiveness [6,7,10–15]. As a
onsequence, we chose to analyze the ADC maps with three differ-
nt sets of ROIs as well as to test three different values of ADC to
revent that the lack of correlation with clinical parameters could
e attributed to the method of analysis. In our series, the correla-
ion of all the tested ADC values with grading and risk classiﬁcation
esulted unsatisfying for both endometrial and cervical cancer. On
he contrary, the DV appeared to be representative of the aggres-
iveness of the tumor.
In conclusion, the DV correlates with grading and risk classiﬁ-
ation of both cervical and endometrial cancers as well as it shows
ow intra-/inter-observer variability. Prospective studies in larger
opulations have to be designed to conﬁrm our observations.
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